GOLDMAN SACHS GROUP INC - APELLIS PHARMACEUTICALS INC ownership

APELLIS PHARMACEUTICALS INC's ticker is APLS and the CUSIP is 03753U106. A total of 209 filers reported holding APELLIS PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.75 and the average weighting 0.4%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of APELLIS PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$13,382,205
-78.5%
351,793
-48.4%
0.00%
-75.0%
Q2 2023$62,102,596
+42.0%
681,697
+2.8%
0.01%
+33.3%
Q1 2023$43,744,342
-21.4%
663,195
-38.4%
0.01%
-25.0%
Q4 2022$55,676,312
-14.9%
1,076,703
+12.4%
0.01%
-20.0%
Q3 2022$65,410,000
+78.5%
957,678
+18.2%
0.02%
+87.5%
Q2 2022$36,647,000
+44.2%
810,399
+62.0%
0.01%
+60.0%
Q1 2022$25,418,000
+7.9%
500,254
+0.4%
0.01%0.0%
Q4 2021$23,549,000
-30.2%
498,082
-51.3%
0.01%
-28.6%
Q3 2021$33,724,000
-23.1%
1,023,170
+47.4%
0.01%
-30.0%
Q2 2021$43,864,000
-9.0%
694,040
-38.2%
0.01%
-16.7%
Q1 2021$48,220,000
-22.6%
1,123,741
+3.1%
0.01%
-25.0%
Q4 2020$62,321,000
+54.0%
1,089,531
-18.8%
0.02%
+45.5%
Q3 2020$40,477,000
+19.7%
1,341,610
+29.6%
0.01%
+10.0%
Q2 2020$33,822,000
+84.4%
1,035,560
+51.3%
0.01%
+66.7%
Q1 2020$18,341,000
+20.2%
684,617
+37.4%
0.01%
+50.0%
Q4 2019$15,262,000
+73.7%
498,435
+36.7%
0.00%
+33.3%
Q3 2019$8,784,000
-17.6%
364,633
-13.4%
0.00%0.0%
Q2 2019$10,665,000
+176.7%
420,856
+113.0%
0.00%
+200.0%
Q1 2019$3,854,000
+402.5%
197,618
+240.1%
0.00%
Q4 2018$767,000
-40.9%
58,108
-20.4%
0.00%
Q3 2018$1,298,000
-8.8%
73,000
+12.9%
0.00%
Q2 2018$1,423,00064,6700.00%
Other shareholders
APELLIS PHARMACEUTICALS INC shareholders Q2 2021
NameSharesValueWeighting ↓
AJU IB Investment Co., Ltd. 1,114,962$63,776,00024.13%
Octagon Capital Advisors LP 548,374$31,367,00010.87%
Ghost Tree Capital, LLC 325,000$18,590,0004.14%
Burrage Capital Management LLC 81,357$4,654,0003.55%
Aufman Associates Inc 53,642$3,068,0002.75%
ACUTA CAPITAL PARTNERS, LLC 167,054$9,555,0002.60%
Cormorant Asset Management, LP 1,866,108$106,741,0002.54%
Tri Locum Partners LP 121,409$6,945,0002.52%
venBio Partners LLC 490,471$28,055,0002.48%
HHLR ADVISORS, LTD. 5,028,289$287,618,0002.29%
View complete list of APELLIS PHARMACEUTICALS INC shareholders